FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016243150> ?p ?o ?g. }

• W2016243150 endingPage "2346" @default.
• W2016243150 startingPage "2341" @default.
• W2016243150 abstract "OBJECTIVES: Proton pump inhibitors (PPIs) are effective in gastroesophageal reflux disease (GERD), but their cost effectiveness is unknown. This is usually determined by cost/quality-adjusted life year (QALY) gained, but whether PPI therapy improves QALYs has not been assessed in a randomized trial. The PPI acid suppression symptom (PASS) test is a five-item questionnaire that identifies patients with persistent acid-related symptoms. We evaluated whether a PASS test-based management strategy of changing GERD therapy to esomeprazole in those with continued symptoms on another PPI or H2 receptor antagonist therapy would be cost effective. We expressed the data in terms of cost per quality-adjusted life months (QALM), as this was a 4-week trial. METHODS: This is a multicenter, cluster-randomized, open-label study in primary care physician centers across Canada. Primary care physician centers were randomized to intervention or control arms. Patients on acid-suppressing medication were identified from primary care records and asked to complete the PASS test. PASS test failures at baseline assessment continued current therapy in control practices or switched to esomeprazole 20 or 40 mg daily (the dose was at the clinician's discretion) for 4 weeks in intervention practices. A planned secondary end point was QALM gain, measured using the validated Euroqol (EQ-5D) completed at baseline and 4 weeks. Medication use was also assessed by questionnaire. Canadian unit generic costs were applied to all GERD drugs, except to esomeprazole and lansoprazole, wherein proprietary costs were used (all costs in Canadian $). Data were analyzed using bootstrap sampling. RESULTS: A total of 1,564 patients were recruited from 134 intervention sites and 92 control sites. Data were evaluable for 808 intervention and 445 control patients. The mean (±standard deviation) QALM at 4 weeks in the intervention group was 0.885±0.164 compared with 0.814±0.179 in the control group, resulting in a mean 0.071 (95% CI=0.091–0.051) QALM gain (P<0.0001). Esomeprazole was cost effective for PASS test failures, with a mean cost of $763 (95% CI=456–1,414) per QALM gain. CONCLUSIONS: Esomeprazole was associated with a statistically significant gain in QALMs and was cost effective in primary care patients with persistent acid-related symptoms identified by the PASS test." @default.
• W2016243150 created "2016-06-24" @default.
• W2016243150 creator A5014881341 @default.
• W2016243150 creator A5039967871 @default.
• W2016243150 creator A5056355381 @default.
• W2016243150 creator A5059184078 @default.
• W2016243150 creator A5061822893 @default.
• W2016243150 creator A5070760244 @default.
• W2016243150 date "2010-11-01" @default.
• W2016243150 modified "2023-09-25" @default.
• W2016243150 title "The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial" @default.
• W2016243150 cites W1905117635 @default.
• W2016243150 cites W1976582380 @default.
• W2016243150 cites W1982919087 @default.
• W2016243150 cites W2002861253 @default.
• W2016243150 cites W2004065292 @default.
• W2016243150 cites W2006632281 @default.
• W2016243150 cites W2009410413 @default.
• W2016243150 cites W2011000634 @default.
• W2016243150 cites W2011237586 @default.
• W2016243150 cites W2023452797 @default.
• W2016243150 cites W2047353965 @default.
• W2016243150 cites W2050850707 @default.
• W2016243150 cites W2055773992 @default.
• W2016243150 cites W2074266195 @default.
• W2016243150 cites W2112688502 @default.
• W2016243150 cites W2122265874 @default.
• W2016243150 cites W2129558138 @default.
• W2016243150 cites W2166715195 @default.
• W2016243150 cites W4248033032 @default.
• W2016243150 doi "https://doi.org/10.1038/ajg.2010.368" @default.
• W2016243150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20842110" @default.
• W2016243150 hasPublicationYear "2010" @default.
• W2016243150 type Work @default.
• W2016243150 sameAs 2016243150 @default.
• W2016243150 citedByCount "39" @default.
• W2016243150 countsByYear W20162431502012 @default.
• W2016243150 countsByYear W20162431502013 @default.
• W2016243150 countsByYear W20162431502014 @default.
• W2016243150 countsByYear W20162431502015 @default.
• W2016243150 countsByYear W20162431502016 @default.
• W2016243150 countsByYear W20162431502017 @default.
• W2016243150 countsByYear W20162431502018 @default.
• W2016243150 countsByYear W20162431502019 @default.
• W2016243150 countsByYear W20162431502020 @default.
• W2016243150 countsByYear W20162431502021 @default.
• W2016243150 countsByYear W20162431502022 @default.
• W2016243150 countsByYear W20162431502023 @default.
• W2016243150 crossrefType "journal-article" @default.
• W2016243150 hasAuthorship W2016243150A5014881341 @default.
• W2016243150 hasAuthorship W2016243150A5039967871 @default.
• W2016243150 hasAuthorship W2016243150A5056355381 @default.
• W2016243150 hasAuthorship W2016243150A5059184078 @default.
• W2016243150 hasAuthorship W2016243150A5061822893 @default.
• W2016243150 hasAuthorship W2016243150A5070760244 @default.
• W2016243150 hasConcept C112930515 @default.
• W2016243150 hasConcept C126322002 @default.
• W2016243150 hasConcept C159110408 @default.
• W2016243150 hasConcept C168563851 @default.
• W2016243150 hasConcept C176400912 @default.
• W2016243150 hasConcept C1862650 @default.
• W2016243150 hasConcept C203092338 @default.
• W2016243150 hasConcept C204243189 @default.
• W2016243150 hasConcept C2777014526 @default.
• W2016243150 hasConcept C2777498785 @default.
• W2016243150 hasConcept C2778204628 @default.
• W2016243150 hasConcept C2778715759 @default.
• W2016243150 hasConcept C2779134260 @default.
• W2016243150 hasConcept C2779951463 @default.
• W2016243150 hasConcept C2781025758 @default.
• W2016243150 hasConcept C3019080777 @default.
• W2016243150 hasConcept C43270747 @default.
• W2016243150 hasConcept C64332521 @default.
• W2016243150 hasConcept C71924100 @default.
• W2016243150 hasConceptScore W2016243150C112930515 @default.
• W2016243150 hasConceptScore W2016243150C126322002 @default.
• W2016243150 hasConceptScore W2016243150C159110408 @default.
• W2016243150 hasConceptScore W2016243150C168563851 @default.
• W2016243150 hasConceptScore W2016243150C176400912 @default.
• W2016243150 hasConceptScore W2016243150C1862650 @default.
• W2016243150 hasConceptScore W2016243150C203092338 @default.
• W2016243150 hasConceptScore W2016243150C204243189 @default.
• W2016243150 hasConceptScore W2016243150C2777014526 @default.
• W2016243150 hasConceptScore W2016243150C2777498785 @default.
• W2016243150 hasConceptScore W2016243150C2778204628 @default.
• W2016243150 hasConceptScore W2016243150C2778715759 @default.
• W2016243150 hasConceptScore W2016243150C2779134260 @default.
• W2016243150 hasConceptScore W2016243150C2779951463 @default.
• W2016243150 hasConceptScore W2016243150C2781025758 @default.
• W2016243150 hasConceptScore W2016243150C3019080777 @default.
• W2016243150 hasConceptScore W2016243150C43270747 @default.
• W2016243150 hasConceptScore W2016243150C64332521 @default.
• W2016243150 hasConceptScore W2016243150C71924100 @default.
• W2016243150 hasIssue "11" @default.
• W2016243150 hasLocation W20162431501 @default.
• W2016243150 hasLocation W20162431502 @default.
• W2016243150 hasOpenAccess W2016243150 @default.
• W2016243150 hasPrimaryLocation W20162431501 @default.

• next